The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.
Medscape News Europe
Source link : https://www.medscape.com/viewarticle/ema-backs-breast-cancer-serd-after-fda-no-vote-2026a1000gsm?src=rss
Author :
Publish date : 2026-05-22 14:17:00
Copyright for syndicated content belongs to the linked Source.
